Chinese pharmaceutical platform Yaoshibang raises $270m
Chinese B2B pharmaceutical trading platform Yaoshibang has raised $270 million from Guangdong Pearl River Investment, Baidu, Sunshine Insurance, Green Pine Capital Partners, Guangzhou government-backed S Fund, and an undisclosed sovereign wealth fund.
Founded in 2015 by a former executive at Chinese real estate portal Soufang.com, the company distributes medicines from upstream drug manufacturers to pharmacies, clinics, and health centers. As of December...
More on Greater China
Latest News
Novo Tellus hits $375m first close on third Indo-Pacific fund
Novo Tellus Capital Partners, an investor in industrial technology assets across the Indo-Pacific region, has reached a first close of approximately USD 375m on its third fund – matching the overall target for the vehicle.
Matrix, HongShan back China's Qihan Biotech
Matrix Partners China and HongShan (formerly Sequioa Capital China) have joined a USD 16m pre-Series B round for Qihan Biotech, a genome editing player active in human and agricultural therapies.
Trifecta closes third India venture debt fund on $214m
Trifecta Capital has closed its third India venture debt fund with about INR 17.8bn (USD 214) in commitments. The initial target was INR 10bn with a greenshoe option of INR 5bn.
ShawKwei commits $34m to US EV battery manufacturer
Asia-focused industrial technology investor ShawKwei & Partners has announced its third investment in a US-based company in three weeks, with a USD 34.3m commitment to battery manufacturer Group14 Technologies.